Exclusive partnership introduces globally benchmarked stem cell processing platform aimed at improving stem cell recovery, quality, and long-term therapeutic potential
Veteran quality professional with over 20 years of industry experience to lead quality operations at Unit-4 API manufacturing facility
New facility will open by October 2026 and house 500 process development specialists
Phase 1 study to evaluate Siglec-6-targeted CAR-T therapy in relapsed or refractory AML and CLL patients, marking a major milestone for T-CURX’s scalable non-viral CAR-T platform
The new institute will strengthen oncology infrastructure in central India with advanced radiation therapy, multidisciplinary expertise, and comprehensive cancer care services
Dr Reddy’s has partnered with MSN Laboratories Private Limited on the product, with Dr Reddy’s holding exclusive US marketing rights while MSN leads development and manufacturing
The new facility aims to accelerate formulation science and application-led research across pharma, biopharma, nutraceuticals, personal care, and home care segments
Patnaik stressed early diagnosis, rapid treatment, and aggressive surveillance as the backbone of elimination efforts
Postal ballot also clears remuneration proposal and new ESOP 2026 scheme, strengthening the company’s leadership and talent retention strategy
Acquisition strengthens integrated radiology and pathology capabilities, enhancing access to advanced diagnostics and preventive healthcare
Subscribe To Our Newsletter & Stay Updated
